Pidotimod is a synthetic dipeptide that exerts immunomodulatory activity, modifying innate and adaptive immunity. Pidotimod firstly acts on Toll-like receptors, then on antigen-presenting cells and other immunocompetent cells. At the cellular level it promotes dendritic cell maturation with upregulation of co-stimulatory molecules and antigen presentation capacity, enhances macrophage and neutrophil functional responses, modulates cytokine balance toward Th1-type mediators, and increases natural killer cell activity and mucosal IgA production. The substance is a low molecular weight, water-soluble peptide-like molecule formulated for oral and liquid presentations; it is characterized analytically by reversed-phase HPLC and LC-MS methods, shows chemical stability across physiological pH ranges, and is eliminated predominantly via renal excretion with clinical dosing regimens established to achieve pharmacodynamic effects without accumulation.
![(5aS,10aR)-dihydro-1H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine-5,8,10(3H,5aH,10aH)-trione](https://veeprho.com/wp-content/uploads/2025/05/VE0024066-Pidotimod-Impurity-Y.png "(5aS,10aR)-dihydro-1H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine-5,8,10(3H,5aH,10aH)-trione")
Parent: Pidotimod
Parent: Pidotimod
Parent: Pidotimod
![3-((6S,8aR)-5,8-dioxohexahydro-1H-thiazolo[3,4-a]pyrazin-6-yl)propanoic acid](https://veeprho.com/wp-content/uploads/2025/05/VE0024068-Pidotimod-Impurity-X.png "3-((6S,8aR)-5,8-dioxohexahydro-1H-thiazolo[3,4-a]pyrazin-6-yl)propanoic acid")
Parent: Pidotimod
Specified related compounds and degradation products for pidotimod typically include N-terminal truncated peptides, C-terminal truncations, deamidation products, oxidized methionine or sulfide-containing analogs, residual synthetic precursors and solvent-related species; these are monitored by HPLC with confirmation by LC-MS. Typical specification limits used in quality control are assay 98.0 to 102.0 percent, individual specified related compounds not greater than 0.3 percent by area, unspecified individual impurities not greater than 0.1 percent by area, and total impurities not greater than 1.0 percent by area; known degradants may have separate tighter limits set at 0.5 percent. Residual solvents are controlled according to ICH Q3C with class 2 solvents avoided and class 3 solvents kept below 0.5 percent w/w when present, heavy metals are controlled to pharmacopeial limits generally below 20 parts per million, and water content for the active pharmaceutical ingredient is typically limited to a maximum of 5.0 percent.
Pidotimod is used as an immunomodulatory agent in formulations intended to support host immune responses; clinically it has been employed to reduce susceptibility to recurrent respiratory infections and to support recovery by modulating innate and adaptive immune functions. Use is guided by national regulatory approvals and product labeling.
Pidotimod acts on innate immune sensors including Toll-like receptors, which drives activation and maturation of antigen-presenting cells such as dendritic cells, enhances phagocyte function and NK cell cytotoxicity, and shifts cytokine profiles to favor cellular immune responses, thereby promoting more effective pathogen recognition and adaptive immune priming.
Pidotimod oral liquid provides a readily dosed, palatable formulation for pediatric and adult patients who require oral administration; the liquid formulation enables accurate dosing, rapid gastrointestinal absorption, and suitability for those with swallowing difficulties while delivering the same immunomodulatory active substance as solid formulations.
Pidotimod has been generally well tolerated in clinical experience when used according to approved indications and dosing; adverse events are usually mild and transient and can include gastrointestinal discomfort and skin reactions. Caution is advised in individuals with known hypersensitivity to the product components, and safety in pregnancy and lactation should be assessed on a case-by-case basis according to available clinical data and regulatory guidance.
